Publications by authors named "K Abdallah"
Background: Thyroid disorders have significant clinical sequelae, including impaired growth in children, metabolic abnormalities, and impaired cognitive function. However, available studies on burden of thyroid diseases in people with human immunodeficiency virus (HIV), particularly its prevalence and its interaction with HIV related factors (like CD4 count), are controversial. This review aimed to provide a comprehensive summary and analysis on the extent of thyroid dysfunctions in this population.
View Article and Find Full Text PDFmRNA therapeutics offer a potentially universal strategy for the efficient development and delivery of therapeutic proteins. Current mRNA vaccines include chemically modified nucleotides to reduce cellular immunogenicity. Here, we develop an efficient, high-throughput method to measure human translation initiation on therapeutically modified as well as endogenous RNAs.
View Article and Find Full Text PDFArticle Synopsis
- - This study examines whether lower doses of anti-PD(L)1 agents are as effective as the standard doses for treating patients with solid tumors at a Brazilian hospital, aiming to highlight cost-effectiveness.
- - A total of 71 patients were analyzed, comparing efficacy outcomes such as clinical overall response rate, progression-free survival, and overall survival between those receiving low-dose (LD) and conventional-dose (CD) treatments.
- - Findings revealed no significant differences in treatment outcomes between LD and CD groups, suggesting that lower doses could provide a more accessible treatment option worth further investigation in future randomized trials.
Metabolic stress must be effectively mitigated for the survival of cells and organisms. Ribosomes have emerged as signaling hubs that sense metabolic perturbations and coordinate responses that either restore homeostasis or trigger cell death. As yet, the mechanisms governing these cell fate decisions are not well understood.
View Article and Find Full Text PDFBackground And Objective: Treatment of sickle cell disease (SCD) has traditionally focused on symptomatic and preventative care. Recent advances in novel therapeutic developments, likely to be orphan-designated, are anticipated to carry a substantial price tag. This study assesses the potential budget impact of adopting disease-modifying treatments, crizanlizumab and voxelotor, and pioneering CRISPR gene-edited therapy, CTX001, in the Belgian healthcare system.
View Article and Find Full Text PDF